SC Engineering "Cellontech's intra-articular injection 'Katizol' treatment effects consecutively published in international journals"

[Asia Economy Reporter Hyunseok Yoo] Cellontech, a regenerative medicine specialized bio company affiliated with SC Engineering, announced on the 21st that a clinical paper proving the therapeutic effect of ‘CartiZol (CartiZol, collagen-based tissue supplement)’, an intra-articular injection using collagen developed for the first time in Korea, has been published in the SCI(E) (Science Citation Index Expanded) international journal 'TERM'.

The paper published in the international journal this time investigated the therapeutic efficacy of intra-articular bio-collagen injection on joint cartilage defects using an animal model. Histological grading quantitative analysis of joint cartilage defects was performed through gross analysis and multiple histopathological examinations.

According to the paper, “The test group injected with bio-collagen (CartiZol) showed a faster regeneration period of the subchondral bone compared to the control group (saline), and demonstrated statistically significant improvements with a structure similar to normal articular cartilage, indicating effectiveness in regenerating defective and damaged cartilage.” It also evaluated that “the treatment method through intra-articular injection of bio-collagen can be used as an effective supplement for joint cartilage treatment.”

A Cellontech official explained, “The therapeutic effect of ‘CartiZol’ has already been proven through clinical trials involving 200 osteoarthritis patients conducted by five university hospitals,” adding, “It is receiving great attention in the osteoarthritis treatment market as an intra-articular injection with large-scale clinical references on safety and efficacy.”

He continued, “▲The histological analysis, which is difficult to perform closely on patients, was conducted through animal experiments to re-verify the joint cartilage treatment effect of ‘CartiZol’ ▲This significantly strengthens the reliability of the therapeutic effect proven through previous large-scale clinical trials.”

‘CartiZol’ is the first and only intra-articular injection using collagen in Korea that supplements defective or damaged joint cartilage by administering bio-collagen intra-articularly, and the related technology has been certified as a New Health Technology (NET) by the Ministry of Health and Welfare.

Cellontech has completed all the necessary approval procedures for commercialization, including obtaining domestic product approval (MFDS), new medical technology recognition (NECA), and health insurance reimbursement registration, and has been actively selling ‘CartiZol’ since June.

Meanwhile, SC Engineering has been selected as the preferred negotiation partner for the acquisition of Cellontech’s management rights by Sewon ENC and is smoothly proceeding with the final procedures for the acquisition of Cellontech.

This content was produced with the assistance of AI translation services.